Tango Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $53,811 |
Gross Profit | -463 | -479 | 53,811 |
EBITDA | -45,050 | -38,325 | 16,429 |
EBIT | -45,513 | -38,804 | 15,874 |
Net Income | -45,514 | -38,749 | 15,884 |
Net Change In Cash | 0 | 0 | 53,811 |
Free Cash Flow | -44,360 | -29,940 | -31,103 |
Cash | 157,828 | 112,279 | 58,338 |
Basic Shares | 143,576 | 116,166 | 110,966 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $62,384 | $42,069 | $36,527 | $24,860 |
Gross Profit | 60,103 | 42,069 | 36,527 | 24,860 |
EBITDA | -99,309 | -127,595 | -99,195 | -109,463 |
EBIT | -101,590 | -130,094 | -101,610 | -111,071 |
Net Income | -101,594 | -130,302 | -101,744 | -108,176 |
Net Change In Cash | 62,384 | 42,069 | 36,527 | 24,860 |
Cost of Revenue | -81,066 | |||
Free Cash Flow | -139,934 | -132,255 | -119,508 | -116,772 |
Cash | 112,279 | 69,530 | 66,385 | 59,968 |
Basic Shares | 116,166 | 109,226 | 94,572 | 87,820 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.37 |
2026-03-31 | -$0.32 |
2025-12-31 | -$0.29 |
2025-09-30 | $0.13 |